Percheron Therapeutics Ltd (PER) - Net Assets

Latest as of June 2025: AU$10.00 Million AUD ≈ $7.08 Million USD

Based on the latest financial reports, Percheron Therapeutics Ltd (PER) has net assets worth AU$10.00 Million AUD (≈ $7.08 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$12.44 Million ≈ $8.80 Million USD) and total liabilities (AU$2.43 Million ≈ $1.72 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Percheron Therapeutics Ltd (PER) asset resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	AU$10.00 Million
% of Total Assets	80.44%
Annual Growth Rate	-2.85%
5-Year Change	74.66%
10-Year Change	118.56%
Growth Volatility	89.57

Percheron Therapeutics Ltd - Net Assets Trend (2001–2025)

This chart illustrates how Percheron Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Percheron Therapeutics Ltd asset portfolio for the complete picture of this company's asset base.

Annual Net Assets for Percheron Therapeutics Ltd (2001–2025)

The table below shows the annual net assets of Percheron Therapeutics Ltd from 2001 to 2025. For live valuation and market cap data, see how much is Percheron Therapeutics Ltd worth.

Year	Net Assets	Change
2025-06-30	AU$10.00 Million ≈ $7.08 Million	+6.84%
2024-06-30	AU$9.36 Million ≈ $6.62 Million	-6.14%
2023-06-30	AU$9.98 Million ≈ $7.06 Million	-52.81%
2022-06-30	AU$21.14 Million ≈ $14.96 Million	+269.12%
2021-06-30	AU$5.73 Million ≈ $4.05 Million	+26.41%
2020-06-30	AU$4.53 Million ≈ $3.21 Million	+61.26%
2019-06-30	AU$2.81 Million ≈ $1.99 Million	-33.44%
2018-06-30	AU$4.22 Million ≈ $2.99 Million	+127.76%
2017-06-30	AU$1.85 Million ≈ $1.31 Million	-59.51%
2016-06-30	AU$4.58 Million ≈ $3.24 Million	-35.46%
2015-06-30	AU$7.09 Million ≈ $5.02 Million	+239.82%
2014-06-30	AU$2.09 Million ≈ $1.48 Million	-55.09%
2013-06-30	AU$4.65 Million ≈ $3.29 Million	-11.75%
2012-06-30	AU$5.27 Million ≈ $3.73 Million	+160.93%
2011-06-30	AU$2.02 Million ≈ $1.43 Million	+50.15%
2010-06-30	AU$1.34 Million ≈ $951.04K	-65.78%
2009-06-30	AU$3.93 Million ≈ $2.78 Million	-38.00%
2008-06-30	AU$6.33 Million ≈ $4.48 Million	+5.27%
2007-06-30	AU$6.02 Million ≈ $4.26 Million	-31.57%
2006-06-30	AU$8.79 Million ≈ $6.22 Million	-19.06%
2005-06-30	AU$10.86 Million ≈ $7.69 Million	-36.59%
2004-06-30	AU$17.13 Million ≈ $12.12 Million	+47.47%
2003-06-30	AU$11.62 Million ≈ $8.22 Million	-13.83%
2002-06-30	AU$13.48 Million ≈ $9.54 Million	-32.71%
2001-06-30	AU$20.03 Million ≈ $14.18 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Percheron Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 10327332000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component	Amount	Percentage
Common Stock	AU$112.05 Million	1120.05%
Other Comprehensive Income	AU$1.62 Million	16.22%
Total Equity	AU$10.00 Million	100.00%

Percheron Therapeutics Ltd Competitors by Market Cap

The table below lists competitors of Percheron Therapeutics Ltd ranked by their market capitalization.

Company	Market Cap
Minaean SP Construction Corp V:MSP	$6.16 Million
Wa Kaolin Ltd AU:WAK	$6.18 Million
Variscan Mines Ltd AU:VAR	$6.18 Million
SG Blocks Inc NASDAQ:SGBX	$6.18 Million
Optima Prima Metal Sinergi JK:OPMS	$6.15 Million
Remsense Technologies Ltd AU:REM	$6.15 Million
Djasa Ubersakti Tbk JK:PTDU	$6.15 Million
East Side Games Group Inc TO:EAGR	$6.14 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Percheron Therapeutics Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 9,363,087 to 10,003,873, a change of 640,786 (6.8%).
Net loss of 14,921,913 reduced equity.
Share repurchases of 864,690 reduced equity.
New share issuances of 14,871,491 increased equity.
Other comprehensive income decreased equity by 99,652.
Other factors increased equity by 1,655,550.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	AU$-14.92 Million	-149.16%
Share Repurchases	AU$864.69K	-8.64%
Share Issuances	AU$14.87 Million	+148.66%
Other Comprehensive Income	AU$-99.65K	-1.0%
Other Changes	AU$1.66 Million	+16.55%
Total Change	AU$-	6.84%

Book Value vs Market Value Analysis

This analysis compares Percheron Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.82x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has increased from 0.01x to 0.82x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2001-06-30	AU$0.61	AU$0.01	x
2002-06-30	AU$0.53	AU$0.01	x
2003-06-30	AU$0.31	AU$0.01	x
2004-06-30	AU$0.33	AU$0.01	x
2005-06-30	AU$0.20	AU$0.01	x
2006-06-30	AU$0.16	AU$0.01	x
2007-06-30	AU$0.08	AU$0.01	x
2008-06-30	AU$0.08	AU$0.01	x
2009-06-30	AU$0.04	AU$0.01	x
2010-06-30	AU$0.02	AU$0.01	x
2011-06-30	AU$0.03	AU$0.01	x
2012-06-30	AU$0.05	AU$0.01	x
2013-06-30	AU$0.03	AU$0.01	x
2014-06-30	AU$0.01	AU$0.01	x
2015-06-30	AU$0.04	AU$0.01	x
2016-06-30	AU$0.03	AU$0.01	x
2017-06-30	AU$0.01	AU$0.01	x
2018-06-30	AU$0.02	AU$0.01	x
2019-06-30	AU$0.01	AU$0.01	x
2020-06-30	AU$0.01	AU$0.01	x
2021-06-30	AU$0.01	AU$0.01	x
2022-06-30	AU$0.03	AU$0.01	x
2023-06-30	AU$0.01	AU$0.01	x
2024-06-30	AU$0.01	AU$0.01	x
2025-06-30	AU$0.01	AU$0.01	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Percheron Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -149.16%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 1.24x
Recent ROE (-149.16%) is below the historical average (-81.94%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2001	-1.97%	-3579.45%	0.00x	1.00x	AU$-2.40 Million
2002	-46.89%	-1545.48%	0.03x	1.14x	AU$-7.67 Million
2003	-52.57%	-1363.37%	0.04x	1.03x	AU$-7.27 Million
2004	-26.90%	-343.75%	0.07x	1.06x	AU$-6.32 Million
2005	-57.67%	-738.90%	0.08x	1.03x	AU$-7.35 Million
2006	-62.12%	-1338.82%	0.04x	1.04x	AU$-6.34 Million
2007	-80.37%	0.00%	0.00x	1.34x	AU$-5.44 Million
2008	-33.73%	-33.39%	0.65x	1.56x	AU$-2.77 Million
2009	-67.47%	-1039.11%	0.05x	1.27x	AU$-3.04 Million
2010	-254.81%	-3325.12%	0.06x	1.35x	AU$-3.56 Million
2011	-89.86%	-1992.91%	0.04x	1.21x	AU$-2.02 Million
2012	-34.21%	-1765.96%	0.02x	1.08x	AU$-2.33 Million
2013	-52.83%	-1209.28%	0.04x	1.12x	AU$-2.92 Million
2014	-144.39%	-3630.45%	0.03x	1.27x	AU$-3.22 Million
2015	9.97%	18.30%	0.50x	1.08x	AU$-2.24K
2016	-54.93%	-251.44%	0.19x	1.16x	AU$-2.97 Million
2017	-148.63%	-3985.82%	0.03x	1.37x	AU$-2.94 Million
2018	-55.22%	-9123.35%	0.01x	1.14x	AU$-2.75 Million
2019	-104.80%	-4449.90%	0.02x	1.32x	AU$-3.23 Million
2020	-130.40%	-19352.12%	0.01x	1.18x	AU$-6.36 Million
2021	-140.73%	-192838.25%	0.00x	1.22x	AU$-8.63 Million
2022	-27.49%	-17003.54%	0.00x	1.06x	AU$-7.93 Million
2023	-114.08%	-2956.41%	0.03x	1.29x	AU$-12.38 Million
2024	-127.30%	0.00%	0.00x	1.55x	AU$-12.86 Million
2025	-149.16%	0.00%	0.00x	1.24x	AU$-15.92 Million

Industry Comparison

This section compares Percheron Therapeutics Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $28,811,870
Average return on equity (ROE) among peers: -1076.62%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Percheron Therapeutics Ltd (PER)	AU$10.00 Million	-1.97%	0.24x	$6.16 Million
Althea Group Holdings Ltd (AGH)	$314.00K	-10209.24%	74.32x	$12.05 Million
BOD Science Ltd (BOD)	$2.07 Million	-368.90%	0.69x	$3.01 Million
BPH Global Ltd (BP8)	$12.64 Million	8.57%	1.99x	$2.62 Million
Cann Group Ltd (CAN)	$84.90 Million	-31.17%	0.64x	$5.62 Million
ECS Botanics Holdings Ltd (ECS)	$22.20 Million	-0.37%	0.18x	$5.65 Million
Ecofibre Ltd (EOF)	$109.94 Million	-13.34%	0.36x	$5.36 Million
Epsilon Healthcare Ltd (EPN)	$21.36 Million	-11.98%	0.03x	$5.51 Million
Elixinol Wellness Ltd (EXL)	$9.16 Million	-115.43%	0.47x	$2.05 Million
IDT Australia Ltd (IDT)	$25.01 Million	-24.32%	0.25x	$12.10 Million
Invion Ltd (IVX)	$529.00K	0.00%	2.90x	$3.76 Million

About Percheron Therapeutics Ltd

AU:PER Australia Drug Manufacturers - Specialty & Generic

Market Cap

$6.16 Million

AU$8.70 Million AUD

Market Cap Rank

#27948 Global

#1502 in Australia

Share Price

AU$0.01

Change (1 day)

+0.00%

52-Week Range

AU$0.01 - AU$0.01

All Time High

AU$0.34